{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:58:12Z","timestamp":1760014692470},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,17]]},"DOI":"10.7759\/cureus.47190","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T11:47:57Z","timestamp":1697543277000},"source":"Crossref","is-referenced-by-count":1,"title":["Real-World Observational Study on Vildagliptin With Insulin (VIL-INS) or Vildagliptin and Metformin With Insulin (VIL-MET-INS) Therapy in Indian Patients With Type 2 Diabetes Mellitus"],"prefix":"10.7759","author":[{"given":"P","family":"Panneerselvam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dibakar","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hema","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Dilip Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Ravi Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pramila","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santosh","family":"Revankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sona","family":"Warrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes - global burden of disease and forecasted trends","volume":"10","author":"Khan MA","year":"2020","unstructured":"Khan MA, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes - global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020, 10:107-11. 10.2991\/jegh.k.191028.001","journal-title":"J Epidemiol Glob Health"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2021.02.016","article-title":"Prevalence and trends of the diabetes epidemic in urban and rural India: a pooled systematic review and meta-analysis of 1.7 million adults","volume":"58","author":"Ranasinghe P","year":"2021","unstructured":"Ranasinghe P, Jayawardena R, Gamage N, Sivanandam N, Misra A. Prevalence and trends of the diabetes epidemic in urban and rural India: a pooled systematic review and meta-analysis of 1.7 million adults. Ann Epidemiol. 2021, 58:128-48. 10.1016\/j.annepidem.2021.02.016","journal-title":"Ann Epidemiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.25259\/IJMS_5_2019","article-title":"Risk factors for type 2 diabetes mellitus: an urban perspective","volume":"71","author":"Patil R","year":"2019","unstructured":"Patil R, Gothankar J. Risk factors for type 2 diabetes mellitus: an urban perspective. Indian J Med Sci. 2019, 71:16-21. 10.25259\/IJMS_5_2019","journal-title":"Indian J Med Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001194","article-title":"Hypoglycemia in patient with type 2 diabetes treated with insulin: it can happen","volume":"8","author":"Heller SR","year":"2020","unstructured":"Heller SR, Peyrot M, Oates SK, Taylor AD. Hypoglycemia in patient with type 2 diabetes treated with insulin: it can happen. BMJ Open Diabetes Res Care. 2020, 8:10.1136\/bmjdrc-2020-001194","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.13307","article-title":"So much insulin, so much hypoglycemia","volume":"174","author":"Lee SJ","year":"2014","unstructured":"Lee SJ. So much insulin, so much hypoglycemia. JAMA Intern Med. 2014, 174:686-8. 10.1001\/jamainternmed.2013.13307","journal-title":"JAMA Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f4533","article-title":"Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis","volume":"347","author":"Goto A","year":"2013","unstructured":"Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013, 347:f4533. 10.1136\/bmj.f4533","journal-title":"BMJ"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2016.11.010","article-title":"Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment","volume":"123","author":"Kanazawa I","year":"2017","unstructured":"Kanazawa I, Tanaka KI, Notsu M, et al.. Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment. Diabetes Res Clin Pract. 2017, 123:9-17. 10.1016\/j.diabres.2016.11.010","journal-title":"Diabetes Res Clin Pract"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies MJ","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al.. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022, 45:2753-86. 10.2337\/dci22-0034","journal-title":"Diabetes Care"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13988","article-title":"Effect of adding vildagliptin to insulin in haemodialysed patients with type 2 diabetes: the VILDDIAL study, a randomized, multicentre, prospective study","volume":"22","author":"Munch M","year":"2020","unstructured":"Munch M, Meyer L, Hannedouche T, et al.. Effect of adding vildagliptin to insulin in haemodialysed patients with type 2 diabetes: the VILDDIAL study, a randomized, multicentre, prospective study. Diabetes Obes Metab. 2020, 22:978-87. 10.1111\/dom.13988","journal-title":"Diabetes Obes Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01593.x","article-title":"Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus","volume":"14","author":"Pan C","year":"2012","unstructured":"Pan C, Xing X, Han P, et al.. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012, 14:737-44. 10.1111\/j.1463-1326.2012.01593.x","journal-title":"Diabetes Obes Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12303","article-title":"Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus","volume":"8","author":"Ning G","year":"2016","unstructured":"Ning G, Wang W, Li L, et al.. Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus. J Diabetes. 2016, 8:345-53. 10.1111\/1753-0407.12303","journal-title":"J Diabetes"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12020","article-title":"Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus","volume":"15","author":"Kothny W","year":"2013","unstructured":"Kothny W, Foley J, Kozlovski P, Shao Q, Gallwitz B, Lukashevich V. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013, 15:252-7. 10.1111\/dom.12020","journal-title":"Diabetes Obes Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S39300","article-title":"Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment","volume":"9","author":"Lukashevich V","year":"2013","unstructured":"Lukashevich V, Schweizer A, Foley JE, Dickinson S, Groop PH, Kothny W. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. Vasc Health Risk Manag. 2013, 9:21-8. 10.2147\/VHRM.S39300","journal-title":"Vasc Health Risk Manag"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v4.i4.151","article-title":"Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes","volume":"4","author":"Kozlovski P","year":"2013","unstructured":"Kozlovski P, Foley J, Shao Q, Lukashevich V, Kothny W. Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes. World J Diabetes. 2013, 4:151-6. 10.4239\/wjd.v4.i4.151","journal-title":"World J Diabetes"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108042","article-title":"Effectiveness, safety, and tolerability of vildagliptin or vildagliptin\/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: the OMEGA study","volume":"162","author":"El Ebrashy I","year":"2020","unstructured":"El Ebrashy I, El Kafrawy N, Raouf R, Yousry D. Effectiveness, safety, and tolerability of vildagliptin or vildagliptin\/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: the OMEGA study. Diabetes Res Clin Pract. 2020, 162:108042. 10.1016\/j.diabres.2020.108042","journal-title":"Diabetes Res Clin Pract"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.6026\/97320630017413","article-title":"Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management","volume":"17","author":"Das S","year":"2021","unstructured":"Das S, Gupta AK, Bandyopadhyaya B, Darla BH, Arya V, Abhyankar M, Revankar S. Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management. Bioinformation. 2021, 17:413-23. 10.6026\/97320630017413","journal-title":"Bioinformation"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrp.2014.04.009","article-title":"Prevalence of dyslipidemia and hypertension in Indian type 2 diabetic patients with metabolic syndrome and its clinical significance","volume":"5","author":"Yadav D","year":"2014","unstructured":"Yadav D, Mishra M, Tiwari A, Bisen PS, Goswamy HM, Prasad GB. Prevalence of dyslipidemia and hypertension in Indian type 2 diabetic patients with metabolic syndrome and its clinical significance. Osong Public Health Res Perspect. 2014, 5:169-75. 10.1016\/j.phrp.2014.04.009","journal-title":"Osong Public Health Res Perspect"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1476333","article-title":"Initial combination therapy with vildagliptin plus metformin in drug-na\u00efve patients with T2DM: a 24-week real-life study from Asia","volume":"34","author":"Chawla M","year":"2018","unstructured":"Chawla M, Kim TH, Mirasol RC, Faruque P, Cooke K, Hours-Zesiger P, Shete A. Initial combination therapy with vildagliptin plus metformin in drug-na\u00efve patients with T2DM: a 24-week real-life study from Asia. Curr Med Res Opin. 2018, 34:1605-11. 10.1080\/03007995.2018.1476333","journal-title":"Curr Med Res Opin"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1019609","article-title":"Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey--GALATA study","volume":"31","author":"Ayvaz G","year":"2015","unstructured":"Ayvaz G, Keskin L, Akin F, Dokmetas HS, Tasan E, Ar IB, Uren E. Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey--GALATA study. Curr Med Res Opin. 2015, 31:623-32. 10.1185\/03007995.2015.1019609","journal-title":"Curr Med Res Opin"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/146662-real-world-observational-study-on-vildagliptin-with-insulin-vil-ins-or-vildagliptin-and-metformin-with-insulin-vil-met-ins-therapy-in-indian-patients-with-type-2-diabetes-mellitus","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:54:08Z","timestamp":1707508448000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/146662-real-world-observational-study-on-vildagliptin-with-insulin-vil-ins-or-vildagliptin-and-metformin-with-insulin-vil-met-ins-therapy-in-indian-patients-with-type-2-diabetes-mellitus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.47190","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,17]]}}}